Trastornos psicóticos: Esquizofrenia - Parte 2 -
Autores: Dr. Gustavo Marcial Guardo, Dr. Pablo Ríos
Trastornos psicóticos:
Trastornos psicóticos: Esquizofrenia (Parte 2) // Referencias bibliográficas 106. Glassman AH: Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66 Suppl 6:5-10. 107. Henderson DC: Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005; 66 Suppl 6:11-20. 108. Cournos F, McKinnon K, Sullivan G: Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005; 66 Suppl 6:27-33. 109. Palmer BA, Pankratz VS, Bostwick JM: The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62(3):247-53. 110. Miles CP: Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977; 164(4):231-46. 111. Barraclough B, Bunch J, Nelson B, Sainsbury P: A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974; 125(0):355- 73. 112. Planansky K, Johnston R: Clinical setting and motivation in suicidal attempts of schizophrenics. Acta Psychiatr Scand 1973; 49(6):680-90. 113. Fenton WS, McGlashan TH, Victor BJ, Blyler CR: Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997; 154(2):199-204. 114. Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H: Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54(3):243-51. 115. Rossau CD, Mortensen PB: Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry 1997; 171:355-9. 116. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2):261-76. 117. Boves J, Portilla M, Bascarán M, P.Sáiz,. MB: Banco de instrumentos básicos para la práctica de la psiquiatría clínica. Barcelona Psiquiatría Editores, 2004. 118. Glashan TM, T TM, Woods W: A scale for the assesment of prodromal symptoms and states, Early intervention in psychotic disorders. Dordrecht, Kluwer Academic Publishers, 2001. 119. Haddock G, McCarron J, Tarrier N, Faragher EB: Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med 1999; 29(4):879- 89. 120. González JC, Sanjuan J, Canete C, Echanove MJ, Leal C: [Evaluation of auditory hallucinations: the PSYRATS scale]. Actas Esp Psiquiatr 2003; 31(1):10-7. 121. Carpenter WT, Jr., Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145(5):578-83. 122. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D: The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986; 143(1):35-9. 123. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM: Assessment of insight in psychosis. Am J Psychiatry 1993; 150(6):873-9. 124. Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13(1):177-83. 125. Rush J, Pincus H, First M, Blacker D, Endicott J, S SK: Handbook of Psychiatric Measures. Washington, DC, American Psychiatric Association, 2000. 126. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149(9):1183-8. 127. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J: The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50(11):884-97. 128. Haas GL, Sweeney JA: Premorbid and onset features of firstepisode schizophrenia. Schizophr Bull 1992; 18(3):373-86. 129. Beiser M, Erickson D, Fleming JA, Iacono WG: Establishing the onset of psychotic illness. Am J Psychiatry 1993; 150(9):1349-54. 130. Olin SC, Mednick SA: Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull 1996; 22(2):223- 40. 131. Hafner H, Maurer K, Loffler W, Riecher-Rossler A: The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162:80-6. 132. Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22(2):353-70. 133. Larsen TK, McGlashan TH, Moe LC: First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996; 22(2):241-56. 134. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56(3):241-7. 135. Birchwood M, Todd P, Jackson C: Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172(33):53-9. 136. Birchwood M, Smith J, Macmillan F, Hogg B, Prasad R, Harvey C, Bering S: Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med 1989; 19(3):649-56. 137. Jorgensen P: Early signs of psychotic relapse in schizophrenia. Br J Psychiatry 1998; 172:327-30. 138. Herz MI, Lamberti JS: Prodromal symptoms and relapse prevention in schizophrenia. Schizophr Bull 1995; 21(4):541-51. 139. Fenton WS, McGlashan TH: Prognostic scale for chronic schizophrenia. Schizophr Bull 1987; 13(2):277-86. 140. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151(10):1409-16. 141. McGlashan TH: A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr Bull 1988; 14(4):515-42. 142. Krausz M, Muller-Thomsen T: Schizophrenia with onset in adolescence: an 11-year follow up. Schizophr Bull 1993; 19(4):831- 41. 143. Fenton WS, McGlashan TH: Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991; 48(11):969- 77. 144. Fenton WS, McGlashan TH: Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48(11):978-86. 145. McGlashan TH, Fenton WS: Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19(1):71-84. 146. McGlashan TH: The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study. Arch Gen Sciens Editorial TratadodeActualizaciónenPsiquiatría 11
CAPÍTULO XV Trastornos psicóticos: Esquizofrenia (Parte 2) // Referencias bibliográficas Psychiatry 1986; 43(2):167-76. 147. Bardenstein KK, McGlashan TH: Gender differences in affective, schizoaffective, and schizophrenic disorders. A review. Schizophr Res 1990; 3(3):159-72. 148. McGlashan TH, Bardenstein KK: Gender differences in affective, schizoaffective, and schizophrenic disorders. Schizophr Bull 1990; 16(2):319-29. 149. McGlashan TH: Schizophrenia: psychosocial therapies and the role of psychosocial factors in its etiology and pathogenesis, in Psychiatry Update. Washington, DC,, American Psychiatric Press, 1986. 150. McGlashan TH, Fenton WS: Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991; 17(4):609-32. 151. McGlashan TH: Predictors of shorter-, medium-, and longerterm outcome in schizophrenia. Am J Psychiatry 1986; 143(1):50-5. 152. McGlashan TH, Williams PV: Predicting outcome in schizoaffective psychosis. J Nerv Ment Dis 1990; 178(8):518-20. 153. Davidson L, McGlashan TH: The varied outcomes of schizophrenia. Can J Psychiatry 1997; 42(1):34-43. 154. Bromet EJ, Fennig S: Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46(7):871-81. 155. Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-7. 156. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP: Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22(3):413-30. 157. Hiroeh U, Appleby L, Mortensen PB, Dunn G: Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001; 358(9299):2110-2. 158. Lieberman JA, Fenton WS: Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 2000; 157(11):1727-30. 159. Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B: Early intervention, untreated psychosis and the course of early schizophrenia. Br J Psychiatry Suppl 1998; 172(33):84-9. 160. Johannessen JO, McGlashan TH, Larsen TK, Horneland M, Joa I, Mardal S, Kvebaek R, Friis S, Melle I, Opjordsmoen S, Simonsen E, Ulrik H, Vaglum P: Early detection strategies for untreated firstepisode psychosis. Schizophr Res 2001; 51(1):39-46. 161. McGlashan TH: Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999; 46(7):899-907. 162. Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. American Psychiatric Association, 2004. 163. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1):82-91. 164. Practice guideline for the Assessment and Treatment of Patients With Suicidal Behaviors, American Psychiatric Association, 2004. 165. Buckley PF, Noffsinger SG, Smith DA, Hrouda DR, Knoll JLt: Treatment of the psychotic patient who is violent. Psychiatr Clin North Am 2003; 26(1):231-72. 166. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1):12-8. 167. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158(7):1149-51. 168. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59(5):441-8. 169. Brook S, Lucey JV, Gunn KP: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61(12):933-41. 170. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2):128-34. 171. Currier GW: Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000; 61 Suppl 14:21-6. 172. Wikinski S, Jufe G: El tratamiento farmacológico enPsiquiatría.Tratamiento farmacológico de la excitación psicomotriz Editorial Médica Panamericana, 2005. 173. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Bmj 2000; 321(7273):1371-6. 174. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A: Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160(2):297-302. 175. Wikinski S, Jufe G: El Tratamiento Farmacológico enPsiquiatría.Tratamiento Farmacológico de la Esquizofrenia. Editorial Médica Panamericana, 2005. 176. Allen MH: Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000; 61 Suppl 14:11-20. 177. Schatzberg. A, 2001. CN: Essentials of clinical psychopharmacology. Washington DC, American Psychiatric Publishing, 2001. 178. American Psychiatric Association: The Practice o Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, Washington, DC, American Psychiatric Association, 2001. 179. Tharyan P, Adams CE: Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2002(2):CD000076. 180. Friedel RO: The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacol Bull 1986; 22(3):928-30. 181. Chanpattana W, Chakrabhand ML: Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome. Psychiatry Res 2001; 105(1-2):107-15. 182. Chanpattana W, Chakrabhand ML, Kongsakon R, Techakasem P, Buppanharun W: Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. J Ect 1999; 15(2):129-39. 183. Kales HC, Dequardo JR, Tandon R: Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23(3):547-56. 184. Kupchik M, Spivak B, Mester R, Reznik I, Gonen N, Weizman A, Kotler M: Combined electroconvulsive-clozapine therapy. Clin Neuropharmacol 2000; 23(1):14-6. 185. Bush G, Fink M, Petrides G, Dowling F, Francis A: Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta 12 Dr. Gustavo Marcial Guardo, Dr. Pablo Ríos
